| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Absolute Lymphocyte Count and Immunoparesis: Impact on Clinical Outcomes for Non-transplant Eligible MM Patients
|
Jimenez-Zepeda, Victor
|
|
2017
|
17 |
1S |
p. e114-e115
nvt p.
|
artikel
|
| 2 |
Absolute Lymphocyte Count and Ratio of Absolute Lymphocyte Count/Absolute Monocyte Count (ALC/AMC) Provides a Readily Available Prognostic Indicator in Multiple Myeloma
|
Kedia, Shweta
|
|
2017
|
17 |
1S |
p. e101-
1 p.
|
artikel
|
| 3 |
A Case Control Study of Syngeneic Transplantation Versus Autologous Transplantation for Multiple Myeloma: Two Decades of Experience at MD Anderson
|
Hosing, Chitra
|
|
2017
|
17 |
1S |
p. e8-
1 p.
|
artikel
|
| 4 |
A Clinico Pathological Profile Analysis of Poems Syndrome A Series of 5 Cases
|
De, Dibyendu
|
|
2017
|
17 |
1S |
p. e148-
1 p.
|
artikel
|
| 5 |
Acute Lymphoblastic Leukemia (ALL) as a Second Primary Malignancy (SPM) After Multiple Myeloma (MM): Secondary Clonally Related Neoplasm or Therapy-Related Leukemia?
|
Aldoss, Ibrahim
|
|
2017
|
17 |
1S |
p. e29-e30
nvt p.
|
artikel
|
| 6 |
Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients With AL amyloidosis Treated With Bortezomib
|
Gavriatopoulou, Maria
|
|
2017
|
17 |
1S |
p. e65-e66
nvt p.
|
artikel
|
| 7 |
A Life in Limbo: Findings from a Study into the Experience of Caring for Myeloma Patients
|
Galinsky, Jayne
|
|
2017
|
17 |
1S |
p. e156-
1 p.
|
artikel
|
| 8 |
A More Mature Immunophenotypic Make-up of Multiple Myeloma Clone(s) at Diagnosis Correlates With a Higher Genomic Instability
|
Martello, Marina
|
|
2017
|
17 |
1S |
p. e11-e12
nvt p.
|
artikel
|
| 9 |
A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)
|
Boccia, Ralph
|
|
2017
|
17 |
1S |
p. e14-
1 p.
|
artikel
|
| 10 |
A Multicenter Phase I/II EMN Study of Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma
|
Gay, Francesca
|
|
2017
|
17 |
1S |
p. e125-e126
nvt p.
|
artikel
|
| 11 |
Analysis of Efficacy and Predictive Factors for Treatment Response of Thalidomide-Containing Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Prior Chemotherapy Including Bortezomib and Lenalidomide
|
Jung, Ki Sun
|
|
2017
|
17 |
1S |
p. e69-
1 p.
|
artikel
|
| 12 |
Analysis of the Availability of Anti-Myeloma Drugs and Impact on the Current Management of Myeloma in Latin American Countries
|
de Magalhaes Filho, Roberto Jose Pessoa
|
|
2017
|
17 |
1S |
p. e15-e16
nvt p.
|
artikel
|
| 13 |
An International, Randomized, Double Blind Trial Comparing Denosumab With Zoledronic Acid (ZA) for the Treatment of Bone Disease in Patients (Pts) With Newly Diagnosed Multiple Myeloma
|
Raje, Noopur
|
|
2017
|
17 |
1S |
p. e27-e28
nvt p.
|
artikel
|
| 14 |
Anti-Myeloma Effects of the Selective JAK1 Inhibitor INCB052793 in Combination with Active Myeloma Agents In Vitro and In Vivo
|
Sanchez, Eric
|
|
2017
|
17 |
1S |
p. e49-e50
nvt p.
|
artikel
|
| 15 |
A Phase 1b Study of Venetoclax Combined with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
|
Moreau, Philippe
|
|
2017
|
17 |
1S |
p. e16-
1 p.
|
artikel
|
| 16 |
A Phase I Clinical Study of Autologous Dendritic Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma
|
Jung, Sung-Hoon
|
|
2017
|
17 |
1S |
p. e129-e130
nvt p.
|
artikel
|
| 17 |
A phase I/IIa Study of the CD38 Antibody MOR202 in Combination With Pomalidomide or Lenalidomide in Patients With Relapsed or Refractory Multiple Myeloma
|
Chatterjee, Manik
|
|
2017
|
17 |
1S |
p. e61-
1 p.
|
artikel
|
| 18 |
A Phase II Study of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone [CDD] for Relapsed or Refractory Multiple Myeloma
|
Fiala, Mark
|
|
2017
|
17 |
1S |
p. e56-
1 p.
|
artikel
|
| 19 |
A Phase 3 Randomized, Open-label Study of Isatuximab (SAR650984) Plus Pomalidomide (POM) and Dexamethasone (DEX) Versus POM and DEX in RRMM
|
Richardson, Paul
|
|
2017
|
17 |
1S |
p. e139-
1 p.
|
artikel
|
| 20 |
A prognostic Scoring System for Patients With Multiple Myeloma Who Were Classified Stage II by Revised International Staging System
|
Jung, Sung-Hoon
|
|
2017
|
17 |
1S |
p. e39-
1 p.
|
artikel
|
| 21 |
A Retrospective Cohort Study to Evaluate the Outcomes of Multiple Myeloma Treated in a Tertiary Care Centre from India
|
Chanana, Raajit
|
|
2017
|
17 |
1S |
p. e92-
1 p.
|
artikel
|
| 22 |
Assessment of Quality of Life in Myeloma Patients Post Autologous Stem Cell Transplant- A Single Centre Experience in South India
|
Damodar, Sharat
|
|
2017
|
17 |
1S |
p. e153-e154
nvt p.
|
artikel
|
| 23 |
Association Between Baseline PET/CT Findings and CD38, CD138 Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients With Multiple Myeloma
|
Cengiz, Arzu
|
|
2017
|
17 |
1S |
p. e33-
1 p.
|
artikel
|
| 24 |
Association Between Treatment Regimen Type in Second-Line Therapy (2LT) and Duration of Therapy (DOT) & Time To Next Treatment (TTNT) in a United States (US) Relapsed/Refractory Multiple Myeloma (RRMM) Cohort
|
Romanus, Dorothy
|
|
2017
|
17 |
1S |
p. e81-e82
nvt p.
|
artikel
|
| 25 |
Asymptomatic Multiple Myeloma – Molecular Background of Progression and Prognosis
|
Seckinger, Anja
|
|
2017
|
17 |
1S |
p. e9-e10
nvt p.
|
artikel
|
| 26 |
Author Abstract Index
|
|
|
2017
|
17 |
1S |
p. 1-11
11 p.
|
artikel
|
| 27 |
Autologous Stem Cell Transplantation in Elderly Multiple Myeloma Patients
|
Staderini, Michela
|
|
2017
|
17 |
1S |
p. e85-e86
nvt p.
|
artikel
|
| 28 |
Autologous Stem Cell Transplant Improves Depth of Response and Outcomes in African American Patients When Compared With Caucasian Patients
|
Jagosky, Megan
|
|
2017
|
17 |
1S |
p. e38-
1 p.
|
artikel
|
| 29 |
Autologous Stem Cell Transplant in Multiple Myeloma: 15 Year Data from Cancer Hospital
|
Yadav, Neha
|
|
2017
|
17 |
1S |
p. e146-
1 p.
|
artikel
|
| 30 |
A Widely Applicable Method for Resolving Therapeutic Monoclonal Drug Interference for Myeloma Patients
|
Mills, John
|
|
2017
|
17 |
1S |
p. e45-
1 p.
|
artikel
|
| 31 |
Aya-Myeloma: Real World, Single Center Experience Over Last 5 Years
|
Yanamandra, Uday
|
|
2017
|
17 |
1S |
p. e54-
1 p.
|
artikel
|
| 32 |
Bendamustine-Bortezomib-Dexamethasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma: A Real-Life Experience
|
Cerchione, Claudio
|
|
2017
|
17 |
1S |
p. e60-e61
nvt p.
|
artikel
|
| 33 |
Bisphosphonate Induced Osteonecrosis of the Jaw (BONJ) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
|
Oduncu, Fuat
|
|
2017
|
17 |
1S |
p. e77-e78
nvt p.
|
artikel
|
| 34 |
B₂-Microglobulin (β₂M) in Renal Disfunction Patients. Effect in Overall Survival in ISS-Subgroups in Newly Diagnosed Multiple Myeloma (NDMM) Patients
|
Cerda, Seila
|
|
2017
|
17 |
1S |
p. e91-e92
nvt p.
|
artikel
|
| 35 |
Bone Marrow DKK-1 Levels Identify Patients With Smoldering Myeloma With Higher Risk of Progression to Active Multiple Myeloma
|
Giuliani, Nicola
|
|
2017
|
17 |
1S |
p. e35-
1 p.
|
artikel
|
| 36 |
Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT without Dexamethasone and Bisphosphonates: Final Analysis of a Prospective Study
|
Terpos, Evangelos
|
|
2017
|
17 |
1S |
p. e143-e144
nvt p.
|
artikel
|
| 37 |
Bortezomib, Lenalidomide and Low-dose Dexamethasone (VRD) Versus Lenalidomide and Low-dose Dexamethasone (Ld) for Newly-diagnosed Multiple Myeloma- A Randomized Phase III Study-Interim Results
|
Mookerjee, Anjali
|
|
2017
|
17 |
1S |
p. e5-e6
nvt p.
|
artikel
|
| 38 |
Bortezomib-Melphalan-Prednisone (VMP) Versus MP as Initial Treatment for Very Elderly Patients With Newly Diagnosed Multiple Myeloma
|
Kim, Min Kyoung
|
|
2017
|
17 |
1S |
p. e70-
1 p.
|
artikel
|
| 39 |
Bortezomib Versus Non-Bortezomib Based Initial Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis
|
Sidana, Surbhi
|
|
2017
|
17 |
1S |
p. e140-e141
nvt p.
|
artikel
|
| 40 |
Cardio-vascular Toxicity in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients Treated With Carfilzomib, Cyclophosphamide and Dexamethasone: Results From an Integrated Analysis of 3 Phase I/II Trials
|
Mina, Roberto
|
|
2017
|
17 |
1S |
p. e7-
1 p.
|
artikel
|
| 41 |
Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients: A Multicenter, Open Label Phase 1/2 Study
|
Bringhen, Sara
|
|
2017
|
17 |
1S |
p. e59-
1 p.
|
artikel
|
| 42 |
Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)
|
Leleu, Xavier
|
|
2017
|
17 |
1S |
p. e7-e8
nvt p.
|
artikel
|
| 43 |
Case Report: 2 Cases of Rare and Aggressive Plasma Cell Leukemia
|
Linn, Swe Mar
|
|
2017
|
17 |
1S |
p. e151-e152
nvt p.
|
artikel
|
| 44 |
Case Report: Deep Sustained Response to Daratumumab Associated with T-cell Expansion in a Patient with Heavily Treated Relapsed and Refractory Myeloma
|
Usmani, Saad
|
|
2017
|
17 |
1S |
p. e86-
1 p.
|
artikel
|
| 45 |
Changes in Cytokine Production and Metabolism in Bone Marrow Mesenchymal Stem Cells in MGUS and Multiple Myeloma are Driven by Hypoxia Induced PADI2 Expression Altering the Transcriptome
|
Pratt, Guy
|
|
2017
|
17 |
1S |
p. e48-
1 p.
|
artikel
|
| 46 |
Changes in Serum B-Cell Maturation Antigen Levels Are a Rapid and Reliable Indicator of Treatment Efficacy for Patients with Multiple Myeloma
|
Udd, Kyle
|
|
2017
|
17 |
1S |
p. e19-e20
nvt p.
|
artikel
|
| 47 |
Characteristics of Chromosome 17p Aberrations Identified by Metaphase Cytogenetics, Interphase FISH and Sequencing in Multiple Myeloma
|
Huh, Jungwon
|
|
2017
|
17 |
1S |
p. e37-
1 p.
|
artikel
|
| 48 |
Characterizing the Amyloidogenic Protein in Patients Progressing to Light Chain Amyloidosis from Asymptomatic Precursor States Using Mass Spectrometry
|
Kourelis, Taxiarchis
|
|
2017
|
17 |
1S |
p. e102-
1 p.
|
artikel
|
| 49 |
Clinical Features and Results of Bortezomib-Melphalan-Prednisone (VMP) as Initial Treatment in Elderly Multiple Myeloma Patients Received Lenalidomide with Dexamethasone (Len/Dex): Subgroup Analysis of Lenalidomide Registry from Korean Multiple Myeloma Working Party (KMM151)
|
Jo, Jae-Cheol
|
|
2017
|
17 |
1S |
p. e129-
1 p.
|
artikel
|
| 50 |
Clinical Impact and Possible Immunosuppressive Function of Soluble B7-H1 (PD-L1) in Multiple Myeloma
|
Sunakawa, Mika
|
|
2017
|
17 |
1S |
p. e110-e111
nvt p.
|
artikel
|
| 51 |
Clinical Profiles and Outcomes in 1203 Newly Diagnosed Patients With Systemic AL Amyloidosis – First Analysis of the ALChemy Study.
|
Manwani, Richa
|
|
2017
|
17 |
1S |
p. e21-e22
nvt p.
|
artikel
|
| 52 |
Combination Bone Marrow Imaging Using PET-MRI in Plasma Cell Dyscrasias: Correlation With Prognostic Laboratory Values and Clinicopathological Diagnosis
|
Tate, Courtney
|
|
2017
|
17 |
1S |
p. e45-e46
nvt p.
|
artikel
|
| 53 |
Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and their Management Strategies: A Need for Clinical Research Priority
|
Tariman, Joseph
|
|
2017
|
17 |
1S |
p. e156-
1 p.
|
artikel
|
| 54 |
Common Reasons for Change of Chemoregimens in Multiple Myeloma: Real World, Single Center Experience
|
Yanamandra, Uday
|
|
2017
|
17 |
1S |
p. e113-
1 p.
|
artikel
|
| 55 |
Comparative Study of 18F-FDG-PET-CT and Magnetic Resonance in the Diagnosis of Smoldering Myeloma and Bone Plasmocytoma
|
Senin, Alicia
|
|
2017
|
17 |
1S |
p. e108-e109
nvt p.
|
artikel
|
| 56 |
Comparison of Bortezomib Versus Non Bortezomib Regimens in the Treatment of Multiple Myeloma: Experience from a Tertiary Care Centre in North India
|
Nityanand, Soniya
|
|
2017
|
17 |
1S |
p. e77-
1 p.
|
artikel
|
| 57 |
Comparison of Haematopoietic Stem Cell Transplantation Approaches in Primary Plasma Cell Leukaemia
|
Lawless, Sarah
|
|
2017
|
17 |
1S |
p. e23-
1 p.
|
artikel
|
| 58 |
Comprehensive Analysis of Transcript Isoforms in Primary Plasma Cell Leukemia and Multiple Myeloma With del(17p) Showed Significant Differences Between Both Dyscrasias
|
de los Angeles Rojas Ricardo, Elizabeta
|
|
2017
|
17 |
1S |
p. e49-
1 p.
|
artikel
|
| 59 |
Copanlisib Has Activity As a Single Agent and in Combination with Carfilzomib and Response Correlates with Phospho-S6 Level
|
Larson, Sarah
|
|
2017
|
17 |
1S |
p. e132-
1 p.
|
artikel
|
| 60 |
Cost- Effective Autologous Stem-Cell Transplantation in Plasma cell disorder: Single Institution Experience. Dr Shailesh Bamborde Dr Chandrakala S Dr Farah Jijina
|
Bamborde, Shailesh
|
|
2017
|
17 |
1S |
p. e152-e153
nvt p.
|
artikel
|
| 61 |
Cost-Effectivenes of Autologous Stem Cell Transplantation (ASCT) in Over 65 Years New Diagnosed Multiple Myeloma (NDMM) Patients
|
Ballina, Belen
|
|
2017
|
17 |
1S |
p. e58-
1 p.
|
artikel
|
| 62 |
Creating a Quality of Life Clinic for Myeloma Patients
|
Burton, Tanya
|
|
2017
|
17 |
1S |
p. e158-e159
nvt p.
|
artikel
|
| 63 |
Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Lenalidomide and Dexamethasone (LD) for the Treatment of Non-Transplant Eligible MM
|
Jimenez-Zepeda, Victor
|
|
2017
|
17 |
1S |
p. e68-
1 p.
|
artikel
|
| 64 |
Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Followed by ASCT with Bor-HDM Conditioning Regimen: A Single Center Experience
|
Jimenez-Zepeda, Victor
|
|
2017
|
17 |
1S |
p. e117-e118
nvt p.
|
artikel
|
| 65 |
Cytoplasmic Transduction Peptide-Fused Recombinant Tumor-Associated Antigens Can Elicit a Potent Myeloma-Specific Cytotoxic T Lymphocyte by Loading Onto Dendritic Cells
|
Lee, Hyun-Ju
|
|
2017
|
17 |
1S |
p. e74-
1 p.
|
artikel
|
| 66 |
Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in RRMM Based on Prior Lines and Treatment Exposure: CASTOR
|
Lentzsch, Suzanne
|
|
2017
|
17 |
1S |
p. e133-
1 p.
|
artikel
|
| 67 |
Daratumumab for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Center Experience
|
Jimenez-Zepeda, Victor
|
|
2017
|
17 |
1S |
p. e67-e68
nvt p.
|
artikel
|
| 68 |
Daratumumab, Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM Based on Prior Lines and Treatment Exposure: POLLUX
|
Dimopoulos, Meletios
|
|
2017
|
17 |
1S |
p. e116-
1 p.
|
artikel
|
| 69 |
Decision Aids Utilized by Patients and Clinicians During Treatment Decision Making for Multiple Myeloma: An Integrative Review
|
Tariman, Joseph
|
|
2017
|
17 |
1S |
p. e159-
1 p.
|
artikel
|
| 70 |
Defining Clonal Plasticity Using Whole Exome Sequencing in Single Cells in an Index Case of amp1q21 Multiple Myeloma
|
Sahota, Surinder
|
|
2017
|
17 |
1S |
p. e108-
1 p.
|
artikel
|
| 71 |
Dendritic Cell Vaccination Combined with Lenalidomide and Programmed Death-1 (PD-1) Blockade has Synergistically Induced a Marked Tumor Regression in a Murine Myeloma Model
|
Vo, Manh-Cuong
|
|
2017
|
17 |
1S |
p. e86-e87
nvt p.
|
artikel
|
| 72 |
Depth of Response and MRD with Daratumumab Plus Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in RRMM: CASTOR
|
Spencer, Andrew
|
|
2017
|
17 |
1S |
p. e85-
1 p.
|
artikel
|
| 73 |
Depth of Response and MRD with Daratumumab Plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM: POLLUX
|
San-Miguel, Jesus
|
|
2017
|
17 |
1S |
p. e17-e18
nvt p.
|
artikel
|
| 74 |
Development of Bone-Targeted Bortezomib to Treat Multiple Myeloma
|
Xing, Lianping
|
|
2017
|
17 |
1S |
p. e87-e88
nvt p.
|
artikel
|
| 75 |
Diagnosis and Monitoring for Light Chain Only and Oligosecretory Myeloma Using Serum Free Light Chain Tests
|
Drayson, Mark
|
|
2017
|
17 |
1S |
p. e96-
1 p.
|
artikel
|
| 76 |
Diarrhea Incidence in Multiple Myeloma Patients Treated With Lenalidomide and Pomalidomide
|
Montefusco, Vittorio
|
|
2017
|
17 |
1S |
p. e46-
1 p.
|
artikel
|
| 77 |
Diffusion Weighted Whole Body MRI for Evaluation of Early Response in Multiple Myeloma
|
Zambello, Renato
|
|
2017
|
17 |
1S |
p. e118-
1 p.
|
artikel
|
| 78 |
Dissecting Genetic Aberrations in Multiple Myeloma Using aCGH and MLPA
|
Gupta, Ritu
|
|
2017
|
17 |
1S |
p. e36-
1 p.
|
artikel
|
| 79 |
Double Autologous Stem Cell Transplantation Followed by Maintenance Therapy Conquers the Adverse Cytogenetic Abnormalities in Newly Diagnosed Multiple Myeloma Patients
|
Motomura, Yotaro
|
|
2017
|
17 |
1S |
p. e136-
1 p.
|
artikel
|
| 80 |
Drug Response Prediction in High Risk Multiple Myeloma
|
Vangsted, Annette Juul
|
|
2017
|
17 |
1S |
p. e130-
1 p.
|
artikel
|
| 81 |
Early Bortezomib Failure Predicts Shorter PFS: A Retrospective Analysis from 4 Tertiary Centres in Victoria, Australia
|
Bergin, Krystal
|
|
2017
|
17 |
1S |
p. e120-e121
nvt p.
|
artikel
|
| 82 |
Easy to Use Integrated Software for Detection and Isotyping of Monoclonal Gammopathies via MALDI Mass Spectrometry
|
Dasari, Surendra
|
|
2017
|
17 |
1S |
p. e94-e95
nvt p.
|
artikel
|
| 83 |
EDO-S101, an Alkylating-HDAC-Inhibitor, is Synergistic With Proteasome Inhibition Against Multiple Myeloma Through Activation of Multiple Pathways
|
Besse, Lenka
|
|
2017
|
17 |
1S |
p. e31-e32
nvt p.
|
artikel
|
| 84 |
Effect of Improvements of Survival, Population Aging and IMWǴ14 Criteria on Incidence and Prevalence of Multiple Myeloma
|
Gonzalez, Paola
|
|
2017
|
17 |
1S |
p. e98-
1 p.
|
artikel
|
| 85 |
Effect of Treatment with Lenalidomide Plus Low-Dose Dexamethasone Until Progression on Health-Related Quality of Life Over Time in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
|
Vogl, Dan T.
|
|
2017
|
17 |
1S |
p. e87-
1 p.
|
artikel
|
| 86 |
Efficacy and Safety of Daratumumab-Based Regimens in Patients with Relapsed/Refractory Multiple Myeloma – A Systematic Literature Review and Network Meta-analysis
|
Dimopoulos, Meletios
|
|
2017
|
17 |
1S |
p. e63-
1 p.
|
artikel
|
| 87 |
Efficacy and Safety of Once-Weekly Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: Secondary Analysis from the CHAMPION-1 Study by Prior Lines of Therapy
|
Berdeja, Jesus
|
|
2017
|
17 |
1S |
p. e58-e59
nvt p.
|
artikel
|
| 88 |
Efficacy and Safety of VTD-PACE Regimen in Relapsed or Refractory Multiple Myeloma
|
Andoh, Shohei
|
|
2017
|
17 |
1S |
p. e57-
1 p.
|
artikel
|
| 89 |
Efficacy and Safety of Weekly Bortezomib Containing VMP Followed By Bortezomib Maintenance Therapy in Unfit or Frail Multiple Myeloma Patients
|
Takezako, Naoki
|
|
2017
|
17 |
1S |
p. e142-e143
nvt p.
|
artikel
|
| 90 |
Efficacy and Tolerability of the Histone-Deacetylase Inhibitor Panobinostat in Clinical Practice
|
Baertsch, Marc-A.
|
|
2017
|
17 |
1S |
p. e119-e120
nvt p.
|
artikel
|
| 91 |
Efficacy of Novel Agents on Soft-tissue Plasmacytomas in Patients with Relapsed Multiple Myeloma
|
Jiménez, Raquel
|
|
2017
|
17 |
1S |
p. e128-
1 p.
|
artikel
|
| 92 |
Elevated Neutrophil-to-Lymphocyte ratio at Day+100 is Associated With Decreased Progression-Free Survival After Hematopoietic Stem Cell Transplantation in Multiple Myeloma
|
Ferreira, Gisela
|
|
2017
|
17 |
1S |
p. e64-e65
nvt p.
|
artikel
|
| 93 |
Elotuzumab in Combination with Pomalidomide and Corticosteroids for Relapsed or Refractory Multiple Myeloma
|
Sidiqi, Hasib
|
|
2017
|
17 |
1S |
p. e83-e84
nvt p.
|
artikel
|
| 94 |
Epidemiological Study of Multiple Myeloma –Retrospective Analysis From a Tertiary Centre
|
Palanisamy, Ayyappan
|
|
2017
|
17 |
1S |
p. e48-
1 p.
|
artikel
|
| 95 |
European Post-Approval Safety Study (EU Pass) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including Second Primary Malignancies, in a Large Cohort of Patients (Pts) Treated With Lenalidomide (LEN), Thalidomide (THAL), and Bortezomib (BORT)
|
Gamberi, Barbara
|
|
2017
|
17 |
1S |
p. e65-
1 p.
|
artikel
|
| 96 |
European Post-Approval Safety Study (EU Pass) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety In Patients (Pts) Treated With Pomalidomide (POM)
|
Di Raimondo, Francesco
|
|
2017
|
17 |
1S |
p. e62-
1 p.
|
artikel
|
| 97 |
Evaluating the Role of Tregs in the Progression of Multiple Myeloma
|
Lad, Deeepesh
|
|
2017
|
17 |
1S |
p. e42-e43
nvt p.
|
artikel
|
| 98 |
Evolutionary Fitness of Relapsed Multiple Myeloma Patients Who Responded to Upfront Combination Therapy Including New Drugs
|
Terragna, Carolina
|
|
2017
|
17 |
1S |
p. e12-
1 p.
|
artikel
|
| 99 |
Exome Sequencing of AL Amyloidosis Reveals Recurrently Mutated Genes
|
Kufova, Zuzana
|
|
2017
|
17 |
1S |
p. e41-e42
nvt p.
|
artikel
|
| 100 |
Expression of MDR1 Mediates Carfilzomib Resistance in MM and PCL Patients and May be Overcome by HIV Protease Inhibitors Nelfinavir and Lopinavir
|
Besse, Andrej
|
|
2017
|
17 |
1S |
p. e32-
1 p.
|
artikel
|
| 101 |
Fate of Ikaros in Multiple Myeloma Cells Upon Treatment With Lenalidomide and Proteasome Inhibitor
|
Ganesan, Saravanan
|
|
2017
|
17 |
1S |
p. e34-e35
nvt p.
|
artikel
|
| 102 |
18FDG-PET Positivity Post Radiotherapy is a Biomarker for Relapse in Patients With Plasmacytoma
|
Sharpley, Faye
|
|
2017
|
17 |
1S |
p. e51-
1 p.
|
artikel
|
| 103 |
18F-FDG PET/CT Findings and Baseline Clinical Parameters in Multiple Myeloma
|
Tuglular, Tulin Firatli
|
|
2017
|
17 |
1S |
p. e148-e149
nvt p.
|
artikel
|
| 104 |
Final Survival Analysis From the FIRST Trial: Lenalidomide Plus Low-Dose Dexamethasone Until Progression (Rd Cont) v Melphalan, Prednisone and Thalidomide (MPT), and Rd for 18 Cycles (Rd18) for Transplant-Ineligible (TNE) Patients (Pts) With Newly Diagnosed Multiple Myeloma
|
Facon, Thierry
|
|
2017
|
17 |
1S |
p. e63-e64
nvt p.
|
artikel
|
| 105 |
Flow Cytometric Immunophenotyping in Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinemia Demonstrates Characteristic Antigen Expression Pattern
|
Sisodiya, Sneha
|
|
2017
|
17 |
1S |
p. e51-e52
nvt p.
|
artikel
|
| 106 |
From Plateau to MRD-Negative CR: Outcomes in the MRC/NCRI Series of Randomised Trials in Newly Diagnosed Patients With Multiple Myeloma From 1980 to 2016
|
Cairns, David
|
|
2017
|
17 |
1S |
p. e60-
1 p.
|
artikel
|
| 107 |
Gamma Heavy Chain Disease-two New Cases with Distinct Clinical Features
|
Teleanu, Maria-Veronica
|
|
2017
|
17 |
1S |
p. e150-
1 p.
|
artikel
|
| 108 |
Global, Prospective, Non-interventional, Observational Study of Disease Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma (MM) Patients (pts): The INSIGHT MM Study (NCT02761187)
|
Rifkin, Robert
|
|
2017
|
17 |
1S |
p. e79-e80
nvt p.
|
artikel
|
| 109 |
Glutamine Deprivation-elicited Sensitization of Multiple Myeloma to Venetoclax is Associated With Electron Transport Chain Inhibition
|
Shanmugam, Mala
|
|
2017
|
17 |
1S |
p. e12-e13
nvt p.
|
artikel
|
| 110 |
Glycosylation of Immunoglobulin Light Chains is Associated with Amyloidosis
|
Milani, Paolo
|
|
2017
|
17 |
1S |
p. e104-
1 p.
|
artikel
|
| 111 |
Going off the “Gold-Standard”: Replacing Electrophoretic Methods With Mass Spectrometry for Plasma Cell Disorders
|
Murray, David
|
|
2017
|
17 |
1S |
p. e18-e19
nvt p.
|
artikel
|
| 112 |
Growth Differentiation Factor 15 (GDF-15) Is a New Biomarker for Overall Survival and Renal Outcomes in Patients with Light Chain (AL) Amyloidosis
|
Kastritis, Efstathios
|
|
2017
|
17 |
1S |
p. e40-
1 p.
|
artikel
|
| 113 |
Health-Related Quality of Life (HRQoL) of Patients (pts) With Newly Diagnosed Multiple Myeloma (NDMM) Receiving Any or Lenalidomide (LEN) Maintenance After Autologous Stem Cell Transplant (ASCT) in the Connect® MM Disease Registry
|
Abonour, Rafat
|
|
2017
|
17 |
1S |
p. e89-e90
nvt p.
|
artikel
|
| 114 |
Heavy+Light Chain and Free Light Chain Assays at Baseline and During Follow-up in EMN02/HO95 Multiple Myeloma Clinical Trial
|
Omedè, Paola
|
|
2017
|
17 |
1S |
p. e47-
1 p.
|
artikel
|
| 115 |
Hepatitis B Virus Reactivation in HBsAg-Negative Patients With Multiple Myeloma: Can Not Be Overlooked in the Endemic Area
|
Hsiao, Liang-Tsai
|
|
2017
|
17 |
1S |
p. e36-e37
nvt p.
|
artikel
|
| 116 |
Hepatitis B Virus Reactivation in Multiple Myeloma Patients in the Era of Novel Agents: a Nationwide Retrospective Study in Japan
|
Tsukune, Yutaka
|
|
2017
|
17 |
1S |
p. e52-
1 p.
|
artikel
|
| 117 |
HES1, a bHLH Transcription Factor Regulate Cell Proliferation and Promotes Apoptosis in Multiple Myeloma Cells
|
Sachithanandan, Sasikala P.
|
|
2017
|
17 |
1S |
p. e48-
1 p.
|
artikel
|
| 118 |
High Cut-off Hemodialysis Combined with Bortezomib-Based Therapy in Multiple Myeloma Patients with Severe Renal Impairment
|
Baertsch, Marc-A.
|
|
2017
|
17 |
1S |
p. e120-
1 p.
|
artikel
|
| 119 |
High Dose Chemotherapy with Autologous Stem Cell Transplantation for Multiple Myeloma: Outcomes at Tata Memorial Centre
|
Gokarn, Anant
|
|
2017
|
17 |
1S |
p. e126-
1 p.
|
artikel
|
| 120 |
High IKAROS Expression in Bone Marrow Environmental, But Not in Myeloma Cells Predicts for Survival with Lenalidomide-Dexamethasone Therapy in Myeloma
|
Bolomsky, Arnold
|
|
2017
|
17 |
1S |
p. e91-
1 p.
|
artikel
|
| 121 |
High Sensitivity Detection of Residual Disease in Multiple Myeloma from Blood
|
Murray, David
|
|
2017
|
17 |
1S |
p. e46-e47
nvt p.
|
artikel
|
| 122 |
Hijacking Myeloma Metabolism to Target Cytotoxic Chemotherapy to Malignant Plasma Cells With Decreased Bone Marrow Toxicity
|
Wiita, Arun
|
|
2017
|
17 |
1S |
p. e53-
1 p.
|
artikel
|
| 123 |
Hyperammonemic Encephalopathy as Initial Presentation of Multiple Myeloma
|
Lico, Albana
|
|
2017
|
17 |
1S |
p. e102-e103
nvt p.
|
artikel
|
| 124 |
Immune Paresis in Treated Multiple Myeloma Involving Adaptive as Well as Innate Immunity: Monocentric Experience of 120 Patients with Serious Infectious Complications Retrospectively Analyzed
|
Torti, Lorenza
|
|
2017
|
17 |
1S |
p. e111-
1 p.
|
artikel
|
| 125 |
Immunophenotyping Patterns of Plasma cells in Plasma Cell Proliferative Disorders
|
Gupta, Ritu
|
|
2017
|
17 |
1S |
p. e99-e100
nvt p.
|
artikel
|
| 126 |
Impact of Chromosomal Aberrations Detected by FISH on Benefits of Autologous Stem Cell Transplantation in Multiple Myeloma Patients
|
Byun, Ja Min
|
|
2017
|
17 |
1S |
p. e149-e150
nvt p.
|
artikel
|
| 127 |
Impact of Early Reduction in Paraprotein on Survival in Transplant Ineligible Myeloma : Lesson from a Tertiary Centre in Rural India
|
Nair, Chandran
|
|
2017
|
17 |
1S |
p. e136-
1 p.
|
artikel
|
| 128 |
Impact of Evolving Pattern in Early Progression of Patients With Smoldering Multiple Myeloma
|
Fernández de Larrea, Carlos
|
|
2017
|
17 |
1S |
p. e23-e24
nvt p.
|
artikel
|
| 129 |
Impact of Frailty on Overall Survival of Elderly Patients With Multiple Myeloma
|
Schutz, Natalia
|
|
2017
|
17 |
1S |
p. e50-
1 p.
|
artikel
|
| 130 |
Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials
|
D'Agostino, Mattia
|
|
2017
|
17 |
1S |
p. e9-
1 p.
|
artikel
|
| 131 |
Improved PFS and OS With Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs Placebo-Rd in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Final Data From the Phase 3 China Continuation of TOURMALINE-MM1
|
Hou, Jian
|
|
2017
|
17 |
1S |
p. e67-
1 p.
|
artikel
|
| 132 |
Improvement of Response for Multiple Myeloma patients on Lenalidomide Maintenance after Autologous Hematopoietic Stem Cell Transplantation (Auto HCT)
|
Shah, Gunjan
|
|
2017
|
17 |
1S |
p. e140-
1 p.
|
artikel
|
| 133 |
IMWG '14 Diagnostic Criteria to Initiate Treatment in New Diagnosed Multiple Myeloma (NDMM): Real-World Stadistics
|
Robles, Violeta Martinez
|
|
2017
|
17 |
1S |
p. e43-e44
nvt p.
|
artikel
|
| 134 |
Incidence and Timing of Graft Versus Host Disease (GVHD) After Daratumumab(Dara) Anti CD38 Therapy Post Allogeneic Transplant (alloHCT)for Myeloma
|
Krishnan, Amrita
|
|
2017
|
17 |
1S |
p. e71-
1 p.
|
artikel
|
| 135 |
Incidence of Secondary Primary Malignancies (SPM) in Patients With Multiple Myeloma (CALM Study)
|
Sahebi, Firoozeh
|
|
2017
|
17 |
1S |
p. e21-
1 p.
|
artikel
|
| 136 |
Incorporation of a Nurse Case Manager for the Diagnosis and Follow Up of Patients with Multiple Myeloma
|
Abella, Eugenia
|
|
2017
|
17 |
1S |
p. e150-e151
nvt p.
|
artikel
|
| 137 |
Increased Mutational Burden and Alterations to DNA Damage Repair Genes are Associated With Poor Prognosis and Sensitivity to PI3K-mTOR Inhibitors in Multiple Myeloma
|
Majumder, Muntasir Mamun
|
|
2017
|
17 |
1S |
p. e2-
1 p.
|
artikel
|
| 138 |
Increase in M2 Macrophage Polarization in Multiple Myeloma Bone Marrow is Inhibited with the JAK2 Inhibitor Ruxolitinib Which Shows Anti-MM Effects
|
Chen, Haiming
|
|
2017
|
17 |
1S |
p. e93-
1 p.
|
artikel
|
| 139 |
Indirubins: A Potential Therapeutic Target in Multiple Myeloma
|
Bagratuni, Tina
|
|
2017
|
17 |
1S |
p. e40-e41
nvt p.
|
artikel
|
| 140 |
Induction Therapy and Thalidomide Based Maintenance in Multiple Myeloma - A Retrospective Analysis from a Tertiary Cancer Center
|
Ramanan, Arun
|
|
2017
|
17 |
1S |
p. e79-
1 p.
|
artikel
|
| 141 |
Infections in Multiple Myeloma: An Understimate Risk Factor of Comorbidity
|
Barilà, Gregorio
|
|
2017
|
17 |
1S |
p. e30-
1 p.
|
artikel
|
| 142 |
Influence of Obesity on Outcomes of Patients with Relapsed Refractory Multiple Myeloma
|
Roy, Vivek
|
|
2017
|
17 |
1S |
p. e139-e140
nvt p.
|
artikel
|
| 143 |
Influence of Predictor Genes of TC Classification on Clinical Outcome in Multiple Myeloma
|
Gupta, Ritu
|
|
2017
|
17 |
1S |
p. e35-e36
nvt p.
|
artikel
|
| 144 |
Integrating Molecular Genetic and Gene Expression Profiling Allows Stratification of Ultra-High Risk Myeloma
|
Sherborne, Amy
|
|
2017
|
17 |
1S |
p. e1-e2
nvt p.
|
artikel
|
| 145 |
Integrative Network Analysis Identifies Novel Drivers of Pathogenesis and Progression in Newly Diagnosed Multiple Myeloma
|
Parekh, Samir
|
|
2017
|
17 |
1S |
p. e13-
1 p.
|
artikel
|
| 146 |
Involvement of a Chondroitin Sulfate Proteolgycan and its Correlation With microRNA in Bone Marrow Microenvironment of Multiple Myeloma
|
Gupta, Nidhi
|
|
2017
|
17 |
1S |
p. e98-e99
nvt p.
|
artikel
|
| 147 |
Is 18F-FDG-PET/CT a Good MRD Marker in Patients with Multiple Myeloma? Comparison and Correlation with Biochemical Markers/ Flow Cytometry
|
Yanamandra, Uday
|
|
2017
|
17 |
1S |
p. e113-e114
nvt p.
|
artikel
|
| 148 |
Is it Useful the Follow Up of MGUS?
|
Ballina, Belen
|
|
2017
|
17 |
1S |
p. e90-
1 p.
|
artikel
|
| 149 |
Isolated Gastrointestinal Graft Versus Host Disease After Autologous Hematopoietic Stem Cell Transplantation in a Patient of Multiple Myeloma
|
Garg, Akanksha
|
|
2017
|
17 |
1S |
p. e154-
1 p.
|
artikel
|
| 150 |
Ixazomib in Combination With Thalidomide and Dexamethasone as Treatment for Patients With Relapsed/Refractory Multiple Myeloma: An Ongoing Phase II Trial
|
Ludwig, Heinz
|
|
2017
|
17 |
1S |
p. e75-
1 p.
|
artikel
|
| 151 |
Late vs Early Response and Depth of Response Are Associated with Improved Outcomes: Post-hoc Analysis of Phase 3 TOURMALINE-MM1 Trial (NCT01564537) in Relapsed/Refractory Multiple Myeloma (RRMM)
|
Garderet, Laurent
|
|
2017
|
17 |
1S |
p. e124-e125
nvt p.
|
artikel
|
| 152 |
Lenalidomide and Low-dose Dexamethasone for Treatment of Relapsed/Refractory Multiple Myeloma: Real-world Treatment Patterns from the PREAMBLE Study
|
Goldschmidt, Hartmut
|
|
2017
|
17 |
1S |
p. e126-e127
nvt p.
|
artikel
|
| 153 |
Lenalidomide at the Dose of Twenty-five mg Every Other Day in Patients Affected by Multiple Myeloma and Renal Failure: A Real-life Experience
|
Cerchione, Claudio
|
|
2017
|
17 |
1S |
p. e122-
1 p.
|
artikel
|
| 154 |
Lenalidomide (LEN) Maintenance Following High-Dose Melphalan and Autologous Stem Cell Transplant (ASCT) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): A Meta-Analysis of Overall Survival (OS)
|
McCarthy, Philip
|
|
2017
|
17 |
1S |
p. e6-
1 p.
|
artikel
|
| 155 |
Length of Hospital Stay is an Independent Predictor of Overall Survival in Patients with systemic AL Amyloidosis
|
Shafì, Ahmed Mohamed Abdel
|
|
2017
|
17 |
1S |
p. e109-
1 p.
|
artikel
|
| 156 |
Long Term Outcomes in Monoclonal Gammopathy of Renal Significance (MGRS)
|
Khera, Akhil
|
|
2017
|
17 |
1S |
p. e24-e25
nvt p.
|
artikel
|
| 157 |
Long-term Reversibility Analysis of Peripheral Neuropathy in Multiple Myeloma Patients Treated with Bortezomib
|
Guiñon, Antonio Garcia
|
|
2017
|
17 |
1S |
p. e123-e124
nvt p.
|
artikel
|
| 158 |
Low Frequency of CD161+CD4+ T Cells Correlate with the Occurrence of Infections in Refractory/Relapsed Multiple Myeloma Patients Receiving Lenalidomide Plus Low-Dose Dexamethasone Treatment
|
Min, Chang Ki
|
|
2017
|
17 |
1S |
p. e76-e77
nvt p.
|
artikel
|
| 159 |
Low-pass Sequencing of Plasma Cell DNA and of ccfDNA for the Detection of Copy Number Aberrations and Early Response Monitoring in Multiple Myeloma
|
Dewaele, Barbara
|
|
2017
|
17 |
1S |
p. e95-
1 p.
|
artikel
|
| 160 |
Lymphocytes Characterization in Patients with IgM Monoclonal Gammopathy
|
Lisenko, Katharina
|
|
2017
|
17 |
1S |
p. e148-
1 p.
|
artikel
|
| 161 |
Maturing Data from the Australia and New Zealand Myeloma and Related Diseases Registry
|
Moore, Elizabeth
|
|
2017
|
17 |
1S |
p. e105-
1 p.
|
artikel
|
| 162 |
Methylation of Multiple Myeloma in Activity and Remission
|
Martinez-Baños, Deborah
|
|
2017
|
17 |
1S |
p. e44-
1 p.
|
artikel
|
| 163 |
Monoclonal Gammopathy Triggering C3 Glomerulopathy: A Rare Association
|
Kumar, Ashwani
|
|
2017
|
17 |
1S |
p. e154-e155
nvt p.
|
artikel
|
| 164 |
Monoclonal Immunoglobulin Deposition Disease and Proliferative Glomerulonephritis With Monoclonal Immunoglobulin disease- How Do They Differ Clinically?
|
Kumar, Rajesh
|
|
2017
|
17 |
1S |
p. e42-
1 p.
|
artikel
|
| 165 |
Mortality by Frailty Status as Defined by a Claims-Based Disability Status in Elderly Patients Newly Diagnosed with Multiple Myeloma in the United States
|
Li, Shuling
|
|
2017
|
17 |
1S |
p. e52-e53
nvt p.
|
artikel
|
| 166 |
Multiple Myeloma Can Be Accurately Diagnosed in Acute Kidney Injury Patients Using a Rapid Serum Free Light Chain Test
|
Drayson, Mark
|
|
2017
|
17 |
1S |
p. e95-e96
nvt p.
|
artikel
|
| 167 |
Multiple Myeloma: Experience in a Tertiary Center in Mexico City
|
Bourlon, Christianne
|
|
2017
|
17 |
1S |
p. e32-e33
nvt p.
|
artikel
|
| 168 |
Multiple Myeloma (MM) and Pure Red Cell Aplasia (PRCA): Interesting Diagnostic and Therapeutic Challenge
|
Cerda, Seila
|
|
2017
|
17 |
1S |
p. e152-
1 p.
|
artikel
|
| 169 |
Multiple Myeloma Standard Dose Versus Fixed Dose- A Comparative Study in Transplant Ineligible Patients
|
Anand, Aravindh Sivanandan
|
|
2017
|
17 |
1S |
p. e84-
1 p.
|
artikel
|
| 170 |
Myanmar Experience of Clinical Response of Patients With Newly Diagnosed Symptomatic Multiple Myeloma Treated with Bortezomib Based or Non-Bordezomib Based Therapy
|
Linn, Swe Mar
|
|
2017
|
17 |
1S |
p. e153-
1 p.
|
artikel
|
| 171 |
MyeNURSE: Development and Use of an E-portal for Nurses to Share Best Practice and Information Resources at the Point of Service
|
King, Tracy
|
|
2017
|
17 |
1S |
p. e158-
1 p.
|
artikel
|
| 172 |
Natural History of t(11;14) Multiple Myeloma
|
Lakshman, Arjun
|
|
2017
|
17 |
1S |
p. e20-
1 p.
|
artikel
|
| 173 |
NEOD001 Demonstrates Organ Biomarker Responses in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction: Results From a Phase 1/2 Study
|
Gertz, Morie A.
|
|
2017
|
17 |
1S |
p. e22-e23
nvt p.
|
artikel
|
| 174 |
Neoplastic Plasma Cells Generate an Inflammatory Environment Within Bone Marrow and Markedly Alter the Distribution of T Cells Between Lymphoid Compartments
|
Pratt, Guy
|
|
2017
|
17 |
1S |
p. e106-e107
nvt p.
|
artikel
|
| 175 |
Neutral Tumor Evolution in Myeloma is Associated With Poor Response to Therapy
|
Johnson, David
|
|
2017
|
17 |
1S |
p. e10-
1 p.
|
artikel
|
| 176 |
Newly Diagnosed Multiple Myeloma is Associated with Hypercoagulablity and High Risk of VTE. The Roadmap Study
|
Fotiou, Despina
|
|
2017
|
17 |
1S |
p. e97-
1 p.
|
artikel
|
| 177 |
Newly Diagnosed Multiple Myeloma (NDMM): Effect of Age, Renal Insufficiency (RI), & Cardiovascular (CV) Disease (dz) on Overall Survival (OS) & Treatment (tx) Patterns Among Stem Cell Transplant (SCT)-Ineligible Patients (pts) in the United States (US)
|
Romanus, Dorothy
|
|
2017
|
17 |
1S |
p. e82-
1 p.
|
artikel
|
| 178 |
Next Generation Sequencing Based Revised International Staging System (R-ISS) for Multiple Myeloma
|
Fiala, Mark
|
|
2017
|
17 |
1S |
p. e18-
1 p.
|
artikel
|
| 179 |
Non-overlapping Promoter and Super-enhancer Driven Processes Support Myeloma Cell Growth and Survival via Distinct Regulatory Axes
|
Fulciniti, Mariateresa
|
|
2017
|
17 |
1S |
p. e1-
1 p.
|
artikel
|
| 180 |
No Relationship Between Delta Neutrophil Index (DNI) and Hospitalization in Elderly Patients with Newly Diagnosed Multiple Myeloma
|
Lee, Yoo Jin
|
|
2017
|
17 |
1S |
p. e132-
1 p.
|
artikel
|
| 181 |
Novel Approach to Study Relationship Between Copy Number Variation and Gene Expression in Multiple Myeloma
|
Brozova, Lucie
|
|
2017
|
17 |
1S |
p. e109-e110
nvt p.
|
artikel
|
| 182 |
Nursing Implications for Patients with Relapsed and/or Refractory Multiple Myeloma Receiving Combination Therapy with Daratumumab (Darzalex™) and Lenalidomide
|
Catamero, Donna
|
|
2017
|
17 |
1S |
p. e159-e160
nvt p.
|
artikel
|
| 183 |
Oligosecretory and Non-Secretory Multiple Myeloma: Incidence, Clinical Characteristics and Outcomes
|
Dimopoulos, Meletios Athanasios
|
|
2017
|
17 |
1S |
p. e115-
1 p.
|
artikel
|
| 184 |
Optimal Timing of Second Transplant in Myeloma Patients Without Optimal Response to First Transplant
|
Park, Seong Kyu
|
|
2017
|
17 |
1S |
p. e78-e79
nvt p.
|
artikel
|
| 185 |
Oral Selinexor Shows Single Agent Activity Enhanced With PI or IMID Combinations in Refractory Multiple Myeloma (MM)
|
Lonial, Sagar
|
|
2017
|
17 |
1S |
p. e13-e14
nvt p.
|
artikel
|
| 186 |
Organ Biomarker Responses in Patients With Light Chain Amyloidosis Treated With NEOD001 Are Independent of Previous Hematologic Response
|
Gertz, Morie A.
|
|
2017
|
17 |
1S |
p. e97-e98
nvt p.
|
artikel
|
| 187 |
Outcome of the Rare Myeloma Subtypes- An Analysis of the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) Data
|
Lawless, Sarah
|
|
2017
|
17 |
1S |
p. e73-
1 p.
|
artikel
|
| 188 |
Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma
|
Garderet, Laurent
|
|
2017
|
17 |
1S |
p. e124-
1 p.
|
artikel
|
| 189 |
Outcome of Very Young (≤ 40 Years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study
|
Abeykoon, Jithma
|
|
2017
|
17 |
1S |
p. e89-
1 p.
|
artikel
|
| 190 |
Outcomes of Consecutive Patients With Newly Diagnosed Myeloma Requiring Dialysis: Dialysis Independence is Associated with Rapid Myeloma Response and Predicts for Longer Survival
|
Dimopoulos, Meletios Athanasios
|
|
2017
|
17 |
1S |
p. e62-e63
nvt p.
|
artikel
|
| 191 |
Overall Survival (OS) and Progression-Free Survival (PFS) Adjusted for Treatment Crossover in the CALGB/ECOG 100104 (Alliance) Study of Lenalidomide (LEN) Versus Placebo (PBO) Maintenance After Stem Cell Transplant (SCT) for Patients With Newly Diagnosed Multiple Myeloma
|
McCarthy, Philip
|
|
2017
|
17 |
1S |
p. e135-
1 p.
|
artikel
|
| 192 |
Overview of Multiple Myeloma in Rwanda
|
Fabien, Ntaganda
|
|
2017
|
17 |
1S |
p. e96-e97
nvt p.
|
artikel
|
| 193 |
Patient Perception of Being Involved in a Clinical Trial for Multiple Myeloma Ceri Bygrave, Tanya Burton*, Patricia Carter, Sarah Richard, Eric Low, Charlotte Bloodworth
|
Burton, Tanya
|
|
2017
|
17 |
1S |
p. e156-e157
nvt p.
|
artikel
|
| 194 |
Patient Reported Symptoms, Concerns and Provider Intervention in Patients with Multiple Myeloma
|
Faiman, Beth
|
|
2017
|
17 |
1S |
p. e158-
1 p.
|
artikel
|
| 195 |
Persistence of Minimal Residual Disease by Multiparameter Flow Cytometry Can Hinder Recovery of Organ Damage in Patients With AL Amyloidosis
|
Milani, Paolo
|
|
2017
|
17 |
1S |
p. e24-
1 p.
|
artikel
|
| 196 |
Phase 1b Study of Daratumumab plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM) with ≥2 Prior Lines of Therapy
|
Chari, Ajai
|
|
2017
|
17 |
1S |
p. e14-e15
nvt p.
|
artikel
|
| 197 |
Phase 2 Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): An Updated Safety Analysis
|
Weisel, Katja
|
|
2017
|
17 |
1S |
p. e145-
1 p.
|
artikel
|
| 198 |
Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM)
|
Facon, Thierry
|
|
2017
|
17 |
1S |
p. e26-e27
nvt p.
|
artikel
|
| 199 |
Phase 2 Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Following Second-Line Lenalidomide (LEN)-Based Treatment (Tx) in Patients (Pts) With Relapsed or Refractory Multiple Myeloma (RRMM): An Updated Analysis of Efficacy and Safety
|
Siegel, David S.
|
|
2017
|
17 |
1S |
p. e141-
1 p.
|
artikel
|
| 200 |
Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
|
Kumar, Shaji
|
|
2017
|
17 |
1S |
p. e131-
1 p.
|
artikel
|
| 201 |
Phase 2 Study Using Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma; Final Analysis (KMM150)
|
Lee, Je-Jung
|
|
2017
|
17 |
1S |
p. e73-e74
nvt p.
|
artikel
|
| 202 |
Phenotypic Analyses of NK Cells in Patients with Multiple Myeloma
|
Kijima, Mika
|
|
2017
|
17 |
1S |
p. e101-e102
nvt p.
|
artikel
|
| 203 |
Physical Exercise Habits of Patients with Multiple Myeloma
|
Hillengass, Michaela
|
|
2017
|
17 |
1S |
p. e160-
1 p.
|
artikel
|
| 204 |
Plasmacytomas in Multiple Myeloma: 45-Years Experience from a Single Institution
|
Rosiñol, Laura
|
|
2017
|
17 |
1S |
p. e107-
1 p.
|
artikel
|
| 205 |
POEMS Syndrome: a Clinical Experience of 48 Patients and Comparative Analysis of Consolidation ASCT Versus Non-ASCT Cohorts
|
Pramanik, Raja
|
|
2017
|
17 |
1S |
p. e106-
1 p.
|
artikel
|
| 206 |
Polyclonal Immunoglobulin Recovery is Enhanced After Autologous Stem Cell Transplant and Associates with Improved Clinical Outcomes in Multiple Myeloma Patients
|
Michallet, Mauricette
|
|
2017
|
17 |
1S |
p. e103-e104
nvt p.
|
artikel
|
| 207 |
Post Autologous Transplant (autoHCT)Therapies in High Risk MM. Subgroup analysis of Phase III BMTCTN 0702 STAMINA: autoHCT Followed by Lenalidomide Maintenance(Len)(AM) vs auto HCT and Len and Bortezomib (BZ) and Dexamethasone Consolidation Len Maintenance(ACM) vs Tandem autoHCT Len Maintenance
|
Krishnan, Amrita
|
|
2017
|
17 |
1S |
p. e5-
1 p.
|
artikel
|
| 208 |
Predictors of Early Treatment Failure following initial therapy for Systemic Immunoglobulin Light Chain Amyloidosis
|
Tandon, Nidhi
|
|
2017
|
17 |
1S |
p. e83-
1 p.
|
artikel
|
| 209 |
Predictors of Treatment (tx) with Triplet First-Line Therapy (1LT) among Transplant-Ineligible Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) in Routine Clinical Care
|
Romanus, Dorothy
|
|
2017
|
17 |
1S |
p. e117-
1 p.
|
artikel
|
| 210 |
Preliminary Results From a Phase Ib Study of Isatuximab in Combination with Pomalidomide (Pom) and Dexamethasone (Dex) in Relapsed and Refractory Multiple Myeloma (RRMM)
|
Richardson, Paul
|
|
2017
|
17 |
1S |
p. e16-e17
nvt p.
|
artikel
|
| 211 |
Pre-Treatment Small Fiber Neuropathy by Sympathetic Skin Response (SSR) Does Not Predict Treatment Emergent Neuropathy in Newly Diagnosed Multiple Myeloma (NDMM) Patients Receiving Bortezomib Based Induction Therapy
|
Lakshman, Arjun
|
|
2017
|
17 |
1S |
p. e72-e73
nvt p.
|
artikel
|
| 212 |
Prevalence and Predictors of Treatment Among Newly Diagnosed Symptomatic Multiple Myeloma (NDMM) Medicare Beneficiaries in the U.S.
|
Romanus, Dorothy
|
|
2017
|
17 |
1S |
p. e114-
1 p.
|
artikel
|
| 213 |
Prevalence and Prognostic Impact of Cytogenetic Abnormalities in 220 Patients With Multiple Myeloma
|
Abe, Yoshiaki
|
|
2017
|
17 |
1S |
p. e29-
1 p.
|
artikel
|
| 214 |
Prevalence of Ocular Disorders in Multiple Myeloma
|
Montefusco, Vittorio
|
|
2017
|
17 |
1S |
p. e104-e105
nvt p.
|
artikel
|
| 215 |
Prior Lenalidomide Resistance and the Impact of IMiD-free Interval in Patients Treated with Pomalidomide and Dexamethasone
|
Dimopoulos, Meletios Athanasios
|
|
2017
|
17 |
1S |
p. e115-e116
nvt p.
|
artikel
|
| 216 |
Profiling of miRnome in Multiple Myeloma
|
Kaur, Gurvinder
|
|
2017
|
17 |
1S |
p. e3-
1 p.
|
artikel
|
| 217 |
Prognostic Implication of Somatic Mutations by Next Generation Sequencing: an Analysis from the MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma Patients
|
D'Agostino, Mattia
|
|
2017
|
17 |
1S |
p. e94-
1 p.
|
artikel
|
| 218 |
Prognostic Value of Diagnostic Bone Marrow Plasma Cell Percentage in Multiple Myeloma
|
Lalayanni, Chrysavgi
|
|
2017
|
17 |
1S |
p. e43-
1 p.
|
artikel
|
| 219 |
Proteasome Inhibitor Based Induction Improves Outcomes Only in Transplant Eligible NDMM Patients
|
Djebbari, Faouzi
|
|
2017
|
17 |
1S |
p. e123-
1 p.
|
artikel
|
| 220 |
Quantification of proteins from CD138-purified myeloma cells using the capillary nano-immunoassay technology is a better predictor of survival than the corresponding gene expression value
|
Misiewicz-Krzeminska, Irena
|
|
2017
|
17 |
1S |
p. e4-e5
nvt p.
|
artikel
|
| 221 |
RAD Regimen Increases Bone Formation and Reduces Bone Resorption and Angiogenesis in Patients with Newly Diagnosed Myeloma: Results of a Phase 2 Study
|
Terpos, Evangelos
|
|
2017
|
17 |
1S |
p. e143-
1 p.
|
artikel
|
| 222 |
RalA and RalB are Potential Therapeutic Targets in Multiple Myeloma Which Mediate Cell Survival Independently of Oncogenic RAS
|
Steinbrunn, Torsten
|
|
2017
|
17 |
1S |
p. e110-
1 p.
|
artikel
|
| 223 |
Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation
|
Qazilbash, Muzaffar
|
|
2017
|
17 |
1S |
p. e138-e139
nvt p.
|
artikel
|
| 224 |
Rapid MALDI-TOF Method for Detecting and Isotyping M-Proteins: Evaluation of Paired Samples of Serum and Urine in Different Clinical Settings
|
Dispenzieri, Angela
|
|
2017
|
17 |
1S |
p. e33-e34
nvt p.
|
artikel
|
| 225 |
Rates and Predictors of Stem Cell Transplant in Elderly Medicare Beneficiaries with Multiple Myeloma in the United States
|
Yong, Candice
|
|
2017
|
17 |
1S |
p. e55-
1 p.
|
artikel
|
| 226 |
Rates of Upfront Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM): A report from the MRDR
|
Bergin, Krystal
|
|
2017
|
17 |
1S |
p. e30-e31
nvt p.
|
artikel
|
| 227 |
Real-World data for the Treatment of Relapsed/Refractory Multiple Myeloma with Lenalidomide and Dexamethasone in 2nd Line (Legend Study): The Prognostic Significance of Biochemical Versus Clinical Relapse
|
Katodritou, Eirini
|
|
2017
|
17 |
1S |
p. e130-e131
nvt p.
|
artikel
|
| 228 |
Real World Data of the Impact of first cycle Daratumumab on Multiple Myeloma and Amyloidosis Services
|
Pandit, Devanshi
|
|
2017
|
17 |
1S |
p. e157-
1 p.
|
artikel
|
| 229 |
Real-World Data on Clinical Characteristics, Prognosis and Outcome of Primary Plasma Cell Leukemia: A Study of the Greek Myeloma Study Group in the Era of Novel Agents
|
Katodritou, Eirini
|
|
2017
|
17 |
1S |
p. e41-
1 p.
|
artikel
|
| 230 |
Real-World Treatment Patterns and Health Care Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Chart Review in France
|
Lin, Huamao Mark
|
|
2017
|
17 |
1S |
p. e134-
1 p.
|
artikel
|
| 231 |
Real-World Treatment Patterns in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Chart Review in the United Kingdom
|
Lin, Huamao Mark
|
|
2017
|
17 |
1S |
p. e133-e134
nvt p.
|
artikel
|
| 232 |
REIIBP is a Histone Methyltransferase Overexpressed in T(4;14) Multiple Myeloma with Oncogenic Potential
|
Xie, Zhigang
|
|
2017
|
17 |
1S |
p. e53-e54
nvt p.
|
artikel
|
| 233 |
Re-immunization following Autologous Hematopoietic Stem Cell Transplantation (Auto HCT) is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance
|
Shah, Gunjan
|
|
2017
|
17 |
1S |
p. e82-e83
nvt p.
|
artikel
|
| 234 |
Relative Dose Intensity (RDI) of Lenalidomide Affects the Outcome of Patients Treated With VRD Consolidation Followed by Autologous Stem Cell Transplantation
|
Komuro, Masato
|
|
2017
|
17 |
1S |
p. e71-
1 p.
|
artikel
|
| 235 |
Repeated Lenalidomide Treatment in Patients With Relapsed Multiple Myeloma
|
Štork, Martin
|
|
2017
|
17 |
1S |
p. e56-e57
nvt p.
|
artikel
|
| 236 |
Response After Induction Therapy in Transplant-eligible Newly-diagnosed Myeloma - a Pooled Analysis from Three Subsequent Multicenter Phase III Trials
|
Mai, Elias K.
|
|
2017
|
17 |
1S |
p. e76-
1 p.
|
artikel
|
| 237 |
Response Assignment Using Hevylite Correlates With Clinical Outcome in Multiple Myeloma
|
Michallet, Mauricette
|
|
2017
|
17 |
1S |
p. e44-e45
nvt p.
|
artikel
|
| 238 |
Role of Multicolor Flow Cytometry in Assessing Bone Marrow Involvement by Solitary Plasmacytoma
|
Tembhare, Prashant
|
|
2017
|
17 |
1S |
p. e25-
1 p.
|
artikel
|
| 239 |
RVD is a Superior Induction Regimen Compared to VCD Among Transplant-Eligible Myeloma Patients
|
Nooka, Ajay
|
|
2017
|
17 |
1S |
p. e137-e138
nvt p.
|
artikel
|
| 240 |
Safety and Engraftment Parameters for Bloodless Transplants among Myeloma Patients
|
Joseph, Nisha
|
|
2017
|
17 |
1S |
p. e68-e69
nvt p.
|
artikel
|
| 241 |
Secondary Malignancies in Patients Undergoing Autologous Hematopoietic Cell Transplant for Multiple Myeloma
|
Vadikoliou, Chrysanthi
|
|
2017
|
17 |
1S |
p. e112-
1 p.
|
artikel
|
| 242 |
Second Stem Cell Transplant in Multiple Myeloma: 15 Year Data from Transplant Centre from India
|
Aggarwal, Mukul
|
|
2017
|
17 |
1S |
p. e118-e119
nvt p.
|
artikel
|
| 243 |
Serum Soluble SLAMF7 is Correlated With Disease Progression in Multiple Myeloma and May Affect Anti-SLAMF7 Antibody Therapy
|
Kaito, Yuta
|
|
2017
|
17 |
1S |
p. e39-e40
nvt p.
|
artikel
|
| 244 |
Single-Arm, Phase 2 Study of Elotuzumab in Combination With Pomalidomide and Dexamethasone in Patients With Multiple Myeloma Who Are Relapsed/Refractory to Lenalidomide: Initial Safety Data
|
Jagannath, Sundar
|
|
2017
|
17 |
1S |
p. e127-
1 p.
|
artikel
|
| 245 |
Single Center Experience with Autologous Stem Cell Transplantation for Multiple Myeloma: A Retrospective Analysis
|
Kumar, Jeevan
|
|
2017
|
17 |
1S |
p. e72-
1 p.
|
artikel
|
| 246 |
SLAM Family Member “CD229”: A Novel Gating Marker for Plasma Cells in Flow Cytometric Immunophenotyping (FCI) of Multiple Myeloma (MM)
|
Ghogale, Sitaram
|
|
2017
|
17 |
1S |
p. e19-
1 p.
|
artikel
|
| 247 |
Splicing fator SRSF1 is dsregulated in Multiple Myeloma With Functional and Clinical Significance
|
Fulciniti, Mariateresa
|
|
2017
|
17 |
1S |
p. e34-
1 p.
|
artikel
|
| 248 |
Stabilization of ATRIP by SHFM1 Regulates Homologous Recombination and Genome Stability in Myeloma
|
Shammas, Masood
|
|
2017
|
17 |
1S |
p. e50-e51
nvt p.
|
artikel
|
| 249 |
Stain Color Normalization and Segmentation of Plasma Cells in Microscopic Images as a Prelude to Development of Computer Assisted Automated Disease Diagnostic Tool in Multiple Myeloma
|
Gupta, Ritu
|
|
2017
|
17 |
1S |
p. e99-
1 p.
|
artikel
|
| 250 |
Subcutaneous Bortezomib in Older Multiple Myeloma Patients (> 75 y/o)
|
Robles, Violeta Martinez
|
|
2017
|
17 |
1S |
p. e103-
1 p.
|
artikel
|
| 251 |
SUMOylation and c-Myc Form Feed-Forward Loop Via miR-34b/c Targeted Gene Expression Program
|
Chen, Yuan
|
|
2017
|
17 |
1S |
p. e122-
1 p.
|
artikel
|
| 252 |
Suppression of Normal B Lymphopoiesis in Bone Marrow Induced by Myeloma Progression
|
Ichii, Michiko
|
|
2017
|
17 |
1S |
p. e37-e38
nvt p.
|
artikel
|
| 253 |
Survival Outcomes of Younger (≤ 50 years) Myeloma Patients
|
Almaula, Dhwani
|
|
2017
|
17 |
1S |
p. e119-
1 p.
|
artikel
|
| 254 |
Symptom Management and Adherence in Multiple Myeloma (MM): A Plan to Disseminate Best- Practice Guidelines for Nurses
|
Faiman, B.
|
|
2017
|
17 |
1S |
p. e160-
1 p.
|
artikel
|
| 255 |
Synchronous Presentation of Smoldering Multiple Myeloma (SMM) and Polycythemia Vera (PV)-A Rare Case Report
|
Barange, Mukesh
|
|
2017
|
17 |
1S |
p. e151-
1 p.
|
artikel
|
| 256 |
Synergistic Antitumor Immunity by Dendritic Cells in Combination with Pomalidomide and Dexamethasone in a Murine Myeloma Model
|
Yang, Seoyun
|
|
2017
|
17 |
1S |
p. e146-e147
nvt p.
|
artikel
|
| 257 |
Systematic Literature Review and Network Meta-Analysis of Treatments for Relapsed/Refractory Multiple Myeloma Patients
|
van Beurden-Tan, Chrissy H.Y.
|
|
2017
|
17 |
1S |
p. e144-
1 p.
|
artikel
|
| 258 |
Table of Contents
|
|
|
2017
|
17 |
1S |
p. A1-
1 p.
|
artikel
|
| 259 |
Targeted Sequencing of Circulating Cell-free DNA in Multiple Myeloma Allows Analysis of Somatic Mutations, Copy Number Aberrations, and Translocations
|
Kis, Olena
|
|
2017
|
17 |
1S |
p. e93-e94
nvt p.
|
artikel
|
| 260 |
Targeting Ongoing DNA Damage in Multiple Myeloma. Effects of Different Inhibitors of the DNA Damage Response on Plasma Cell Survival
|
Herrero, Ana B.
|
|
2017
|
17 |
1S |
p. e100-
1 p.
|
artikel
|
| 261 |
Ten Year Data of Multiple myeloma Patients Treated at a Tertiary Care Centre in Western India
|
Patil, Vinod
|
|
2017
|
17 |
1S |
p. e105-e106
nvt p.
|
artikel
|
| 262 |
The Effect of Clinically Relevant Concentrations of Daratumumab on the Performance of Freelite® Immunoassays
|
Jenner, Ellen
|
|
2017
|
17 |
1S |
p. e127-e128
nvt p.
|
artikel
|
| 263 |
The Efficacy and Safety of Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma in Real Clinical Practice : A Study of the Korean Multiple Myeloma Working Party (KMMWP)
|
Lee, Ho Sup
|
|
2017
|
17 |
1S |
p. e74-e75
nvt p.
|
artikel
|
| 264 |
The efficacy of Salvage Autologous Stem Cell Transplant for Patients With Multiple Myeloma Who Received Maintenance Therapy Post an Initial Transplant
|
King, Justin
|
|
2017
|
17 |
1S |
p. e70-e71
nvt p.
|
artikel
|
| 265 |
The Impact of Maintenance Lenalidomide and Depth of Response on the Mutational Status of the Myeloma Clone from Presentation to Relapse
|
Jones, John
|
|
2017
|
17 |
1S |
p. e100-e101
nvt p.
|
artikel
|
| 266 |
The Impact of Thalidomide, Zoledronate and High-dose Therapy with Autologous Stem Cell Support on Patient Reported Outcomes in Multiple Myeloma: Results of the Quality of Life Substudy of the MRC Myeloma IX Randomised Controlled Trial
|
Cairns, David
|
|
2017
|
17 |
1S |
p. e121-e122
nvt p.
|
artikel
|
| 267 |
The Multiple Myeloma Genome Project: Development of a Molecular Segmentation Strategy for Risk Stratification of Multiple Myeloma (MM)
|
Samur, Mehmet
|
|
2017
|
17 |
1S |
p. e26-
1 p.
|
artikel
|
| 268 |
The outcomes of Korean Patients With Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160)
|
Jung, Sung-Hoon
|
|
2017
|
17 |
1S |
p. e38-e39
nvt p.
|
artikel
|
| 269 |
The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients With MDS/AML-Related Somatic Mutations And Inferior Survival
|
Paiva, Bruno
|
|
2017
|
17 |
1S |
p. e11-
1 p.
|
artikel
|
| 270 |
The Real-World Characteristics and Outcomes of Newly Diagnosed Myeloma Patients Ineligible for Clinical Trials
|
Fiala, Mark
|
|
2017
|
17 |
1S |
p. e55-e56
nvt p.
|
artikel
|
| 271 |
Top-Down Immunoglobulin Light chain Sequence Determination in Patients with POEMS Syndrome
|
Vanderboom, Patrick
|
|
2017
|
17 |
1S |
p. e112-e113
nvt p.
|
artikel
|
| 272 |
Total Dose But Not Combination of Bortezomib Regimen Influences Outcomes in Multiple Myeloma
|
Srinivasan, Anand
|
|
2017
|
17 |
1S |
p. e78-
1 p.
|
artikel
|
| 273 |
To Treat or not to Treat: Hyperelderly Multiple Myeloma
|
Panitsas, Fotios
|
|
2017
|
17 |
1S |
p. e138-
1 p.
|
artikel
|
| 274 |
Towards Response-Adaptive Changes in Induction Therapy to Improve Survival Outcomes in Transplant Eligible Multiple Myeloma Patients
|
Brown, Taylor
|
|
2017
|
17 |
1S |
p. e59-e60
nvt p.
|
artikel
|
| 275 |
Toxicity and Benefit of Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma
|
Maia, Tânia
|
|
2017
|
17 |
1S |
p. e134-e135
nvt p.
|
artikel
|
| 276 |
Transcriptional Programs Associated with Extra-medullary Tumor Progression in Multiple Myeloma
|
Ryu, Daeun
|
|
2017
|
17 |
1S |
p. e107-e108
nvt p.
|
artikel
|
| 277 |
Treatment Patterns and Outcomes in Clinical Practice Among Patients with Newly-Diagnosed Multiple Myeloma: Systematic Literature Review
|
Yong, Candice
|
|
2017
|
17 |
1S |
p. e54-e55
nvt p.
|
artikel
|
| 278 |
Treatment Patterns From 2009-2015 in Patients With Newly Diagnosed Multiple Myeloma in the United States: A Report From the Connect® MM Registry
|
Rifkin, Robert
|
|
2017
|
17 |
1S |
p. e20-e21
nvt p.
|
artikel
|
| 279 |
Treatment (tx) Patterns & Outcomes by Line of Therapy (LOT) in a Large United States (US) Cohort of Transplant-Ineligible Patients (pts) with Multiple Myeloma in the Era of Novel Agents
|
Romanus, Dorothy
|
|
2017
|
17 |
1S |
p. e80-e81
nvt p.
|
artikel
|
| 280 |
Triplet Therapy & Overall Survival (OS) in Routine Practice among Transplant-Ineligible Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the United States (US)
|
Romanus, Dorothy
|
|
2017
|
17 |
1S |
p. e80-
1 p.
|
artikel
|
| 281 |
Unveiling the Biomarker Potential of Shelterin Complex in Myeloma and Revealing Their Role as Therapeutic Targets
|
Kumar, Raman
|
|
2017
|
17 |
1S |
p. e4-
1 p.
|
artikel
|
| 282 |
Updated Results from ASPIRE and ENDEAVOR, Randomized, Open-Label, Multicenter Phase 3 Studies of Carfilzomib in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
|
Siegel, David S.
|
|
2017
|
17 |
1S |
p. e142-
1 p.
|
artikel
|
| 283 |
Upfront Tandem Auto-Allo Transplant in Multiple Myeloma: Long-Term Follow-Up and Impact of “New Drugs” at Relapse
|
Giaccone, Luisa
|
|
2017
|
17 |
1S |
p. e66-e67
nvt p.
|
artikel
|
| 284 |
Use of 18-F FDG PET / CT Scanning Into the First Follow Up of Patients with Multiple Myeloma and Association with Biochemical Response
|
Gironella, Mercedes
|
|
2017
|
17 |
1S |
p. e149-
1 p.
|
artikel
|
| 285 |
Use of the Hevylite™ Assay as an Early Predictive Tool in MGUS and Smoldering Myeloma Transformation, as Well as Myeloma Relapse: Results from the EU FP7 Project OPTATIO
|
Willenbacher, Ella
|
|
2017
|
17 |
1S |
p. e145-e146
nvt p.
|
artikel
|
| 286 |
Utility of the New Versus Old Immunophenotypic Markers in the Flow Cytometric Immunophenotyping of Multiple Myeloma
|
Chatterjee, Gaurav
|
|
2017
|
17 |
1S |
p. e92-e93
nvt p.
|
artikel
|
| 287 |
Validation of Frailty Assessment in Multiple Myeloma (MM) Patients
|
Nikolaou, Eftychia
|
|
2017
|
17 |
1S |
p. e137-
1 p.
|
artikel
|
| 288 |
Venetoclax as Targeted Therapy for Relapsed/Refractory Multiple Myeloma
|
Kumar, Shaji
|
|
2017
|
17 |
1S |
p. e27-
1 p.
|
artikel
|
| 289 |
VTD in Older Patients Comparative With Younger
|
Ballina, Belen
|
|
2017
|
17 |
1S |
p. e57-e58
nvt p.
|
artikel
|
| 290 |
Welcome Message
|
|
|
2017
|
17 |
1S |
p. A3-
1 p.
|
artikel
|
| 291 |
Whole-exome Sequencing and Ultra Low Pass-whole Genome Sequencing of cfDNA and CTCs Enable a Comprehensive Mutational Landscape of Multiple Myeloma
|
Manier, Salomon
|
|
2017
|
17 |
1S |
p. e3-
1 p.
|
artikel
|
| 292 |
Workshop
|
|
|
2017
|
17 |
1S |
p. A2-
1 p.
|
artikel
|
Tijdschrift beschrijving